問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Veterans General Hosptial (在職)

Division of Rheumatology

更新時間：2023-09-19

顏伶容
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏伶容

List

30Cases

2011-02-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2016-12-01 - 2021-12-31

Phase III

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

  • Condition/Disease

    Rheumatoid arthritis

  • Test Drug

    Filgotinib

Participate Sites
12Sites

Terminated11Sites

方耀凡
Linkou Chang Gung Medical Foundation

藍忠亮
China Medical University Hospital-Taipei

未分科

2020-02-27 - 2024-01-31

Phase III

A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    (1) Filgotinib; (2) Adalimumab

Participate Sites
13Sites

Terminated13Sites

2017-07-01 - 2022-01-01

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthritis

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
9Sites

Not yet recruiting8Sites

2020-08-01 - 2023-06-26

Phase III

A two-year, phase III randomized, double-blind, parallel-group, placebocontrolled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis

  • Condition/Disease

    active lupus nephritis

  • Test Drug

    AIN457

Participate Sites
4Sites

Recruiting4Sites

2021-11-01 - 2023-03-02

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-12-31 - 2023-12-31

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren’s Syndrome (SS)

  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    VIB4920

Participate Sites
5Sites

Recruiting5Sites

2016-09-30 - 2019-12-31

Phase II

A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis

  • Condition/Disease

    Active psoriatic arthritis

  • Test Drug

    BI655066

Participate Sites
9Sites

Terminated7Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

黃春明
China Medical University Hospital-Taipei

未分科

2017-01-01 - 2020-06-30

Phase III

A Phase 3 Multicenter, Randomized, Double-blind,Placebo-controlled Study with an Open Label Extension to Evaluatethe Efficacy and Safety of KHK4827 in Subjects with Axial Spondyloarthritis

  • Condition/Disease

    Axial Spondyloarthritis

  • Test Drug

    KHK4827 (Brodalumab)

Participate Sites
13Sites

Terminated11Sites

羅淑芬
Linkou Chang Gung Medical Foundation

黃春明
China Medical University Hospital-Taipei

未分科

2014-07-31 - 2017-03-30

Others

A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis

  • Condition/Disease

    Severely Active Rheumatoid Arthritis

  • Test Drug

    Tofacitinib (Xeljanz)

Participate Sites
6Sites

Terminated6Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB